naltrexone has been researched along with guanidine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ferguson, DM; Jones, RM; Metzger, TG; Portoghese, PS; Sharma, SK | 1 |
| Li, W; Qiu, ZB; Tang, Y; Zheng, YL | 1 |
1 review(s) available for naltrexone and guanidine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for naltrexone and guanidine
| Article | Year |
|---|---|
Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'- to 6'-position of naltrindole.
Topics: Animals; Cell Line; Cloning, Molecular; Guanidine; Guinea Pigs; Humans; In Vitro Techniques; Molecular Conformation; Muscle Contraction; Muscle, Smooth; Mutagenesis, Site-Directed; Naltrexone; Narcotic Antagonists; Rats; Receptors, Opioid, kappa; Structure-Activity Relationship; Transfection | 2001 |
Molecular modeling and 3D-QSAR studies of indolomorphinan derivatives as kappa opioid antagonists.
Topics: Amino Acid Sequence; Animals; Cattle; Conserved Sequence; Guanidine; Guanidines; Humans; In Vitro Techniques; Indoles; Models, Molecular; Molecular Sequence Data; Morphinans; Naltrexone; Protein Conformation; Quantitative Structure-Activity Relationship; Receptors, Opioid, kappa; Rhodopsin; Sequence Homology, Amino Acid | 2006 |